arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

ADMA BIOLOGICS, INC.

ADMA
$9.88 ▼ -0.17 (-1.74%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
72 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
77
Health
Good
Bullish
auto_awesome

Analytical Summary

ADMA BIOLOGICS, INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $2.3B
Dividend Yield
Revenue Growth -0.3%
Op. Margin 50.9%
ROIC 7.9%
FCF / Share $0.24
Trailing P/E 52.0x
Price / Book 5.9x
FCF Yield 2.4%
Debt / Equity 0.50
info Valuation on last close. End-of-day price, Aug 7, 2026.

72-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$114.49M
— -0.3%
Net Income Profit after all expenses
$45.33M
↑ +68.5%
Operating Margin Operating profit as % of sales
50.9%
↑ +12.9% 92th
FCF / Share Free cash flow per share
$0.24
↑ +5337.5%
Long-Term Debt Long-term obligations
$196.87M
↑ +172.9%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
76
Returns
93
Financial Health
83
Cash Quality
29

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 72 quarters